What type of drug does resmetirom belong to?

Resmetirom - Rezdiffra has gradually become the focus of attention of the medical community and patient groups in recent years. It is an oral thyroid hormone receptor beta (THR-β) selective agonist. The unique feature of this type of drug is that it can specifically act on liver metabolic pathways to improve lipid metabolism and inflammatory response. Unlike traditional lipid-lowering drugs or anti-inflammatory drugs, rismetirol does not act solely on blood lipid levels, but by targeting receptors in liver cells, promoting fatty acid oxidation and reducing liver fat accumulation, fundamentally intervening in the pathological process of non-alcoholic steatohepatitis (NASH).

NASH is a chronic disease caused by abnormal deposition of fat in the liver. It is often accompanied by obesity, type 2 diabetes and metabolic syndrome. It may lead to liver fibrosis or even cirrhosis after progression. For a long time, there has been a lack of specific clinical drugs for NASH, and treatment has mostly relied on diet control and exercise intervention. The emergence of resmetirol has filled this gap. According to overseas research data, the efficacy of this drug is mainly focused on improving moderate to severe liver fibrosis (corresponding to stages F2 to F3), and it is recommended to be combined with lifestyle management to achieve maximum value.

From a pharmacological classification point of view, rismetirox is not directly classified as a common lipid-lowering drug, anti-fibrotic drug or immunosuppressant, but is positioned as an innovative targeted drug for metabolic liver diseases. It selectively activates THR-β receptors and avoids the possible side effects of traditional thyroid hormones on the heart or skeletal system, thus having obvious advantages in terms of safety and targeting.

Globally, rismetirol is considered to be one of the first targeted NASH drugs to enter the market Marking a new stage in the research and development of steatohepatitis drugs. For the majority of NASH patients, it not only means an opportunity to delay disease progression, but may also become an alternative to high-risk treatments such as liver transplantation in the future.

Reference materials:https://www.drugs.com/monograph/resmetirom.html